ISAL 2023 | Maintenance therapy in AML: agents under investigation and future outlooks
Thomas Cluzeau
• 20 Mar 2023
Thomas Cluzeau, MD, PhD, University Hospital of Nice, Nice, France, shares some insights into the evolution of maintenance therapy in acute myeloid leukemia (AML). Dr Cluzeau gives an overview of agents currently being explored, including midostaurin, gilteritinib and oral azacitidine, and further comments on the need for more data in this space. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Jazz, Astellas, Arog, Novartis
